Short summary: A randomized trial published in The Lancet found that adults who continued tirzepatide after major weight loss maintained more of that weight loss than those switched to placebo.
Key takeaways
- SURMOUNT-MAINTAIN studied long-term weight maintenance after tirzepatide-assisted weight loss.
- Continuing tirzepatide helped participants maintain more weight loss than switching to placebo.
- A lower 5 mg dose also helped maintain weight loss, though less than the maximum tolerated dose.
- The study did not include people with type 2 diabetes.
What happened?
A randomized trial published in The Lancet looked at a question many people ask about modern obesity medicines: what happens after major weight loss has already been achieved?
The SURMOUNT-MAINTAIN trial enrolled 441 adults with obesity or overweight and at least one weight-related health condition. Participants first received once-weekly tirzepatide during a 60-week open-label weight-loss period.
After this phase, 378 participants who had lost at least 5% of their body weight and could tolerate tirzepatide were randomized into three groups: continuing their maximum tolerated dose, reducing to 5 mg, or switching to placebo.
By week 112, average weight change from baseline was:
- 21.9% lower with continued maximum tolerated tirzepatide
- 16.6% lower with tirzepatide 5 mg
- 9.9% lower with placebo
People who switched to placebo were more likely to regain a substantial amount of the weight they had lost.
Why this matters
Obesity is a chronic medical condition, not simply a short-term willpower problem. Many people regain weight after stopping treatment, whether the treatment is lifestyle-based, medication-based, or surgical.
This study adds evidence that some people may need long-term treatment to maintain weight loss and related health improvements. It also gives useful information about a lower-dose maintenance approach. In the trial, reducing to 5 mg still helped maintain weight loss better than placebo, although the maximum tolerated dose had the strongest effect.
What this does not mean
This does not mean everyone should stay on the same medicine forever. It also does not mean people should reduce, stop, or restart tirzepatide without medical advice.
The trial population matters: SURMOUNT-MAINTAIN studied adults with obesity or overweight without type 2 diabetes. Results may differ in people with diabetes, older adults, people with different medical conditions, or people who cannot tolerate the medicine.
Gastrointestinal side effects, such as nausea, diarrhea, vomiting, and constipation, were the most common adverse events.
Practical takeaway
For people using tirzepatide for obesity treatment, this study supports a planned long-term conversation with a healthcare professional. That conversation should include dose, benefits, side effects, cost, weight regain risk, nutrition, physical activity, and personal preferences.
Sources
Editorial verification note: reviewed for medical accuracy, diabetes-population caveats, medication-safety framing, and source consistency. Independent OpenRouter/Perplexity verification passed against the cited sources.